 NB. PIK3CA mutation may be assessed in archival tumour samples, fresh tumour samples, or in circulating free DNA extracted from plasma or serum. A mutation will be considered pathogenic if described to be recurrent somatic mutation in COSMIC Other cancers with relevant genetic aberrations e.g. KRAS mutations may be considered, depending on emerging preclinical and clinical data on these novel antitumour agents 